1 January 2022 in BioMed Research International
Introduction. Brain metastases (BMs) are common in non‐small‐cell lung cancer (NSCLC), which leads to a poor prognosis. As the two most effective strategies available, the use of combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and radiotherapy (RT) is still controversial. This protocol proposes a methodology for carrying out a systematic review and meta‐analysis that is aimed at (1) focusing on the efficacy and safety role of EGFR‐TKIs combined with RT for BMs from NSCLC and (2) displaying the difference in efficacy of EGFR‐TKIs owing to the sites and number of BMs, different types of RT, EGFR mutation status, and the subtypes of EGFR mutations by subgroup analysis. Methods and Analysis. Electronic databases including PubMed, Embase, CENTRAL, Web of Science, CBM, CNKI, Wanfang database, and VIP database will be searched from their inception until May 2022. Only randomized controlled trials evaluating the clinical efficacy and safety of EGFR‐TKIs combined with RT on BMs of NSCLC will be included. Two reviewers will select the articles, assess the risk of bias, and extract data independently and in duplicate. The RoB 2 tool will be used to assess the quality of included studies. The meta‐analysis of data synthesis will be performed with Stata 16. Publication bias will be assessed with the funnel plot method and the Egger test. Quality of the evidence will be evaluated by the GRADE system. Discussion. The approval of an ethical committee is not required. All the included trials will comply with the current ethical standards and the Declaration of Helsinki. Given the ongoing controversies regarding the optimal sequencing of the available and expanding treatment options for EGFR‐TKIs in NSCLC with BMs, a synthesis of available, high‐quality clinical research evidence is essential to advance our understanding in the treatment of this complex and common disease. This systematic review will evaluate available evidence, will try to provide optimized advice in the applications of EGFR‐TKIs, and will be published in a high‐quality journal. This study is registered with PROSPERO registration number CRD42021291509.
24 June 2021 in Evidence-Based Complementary and Alternative Medicine
Background. Tumor microenvironment (TME) takes a vital effect on the occurrence and development of cancer. Radix Rhei Et Rhizome (RRER, Da-Huang in pinyin), a classical Chinese herb, has been widely used in gastric cancer (GC) for many years in China. However, inadequate systematic studies have focused on the anti-GC effect of RRER in TME. This study intended to uncover the mechanism of it by network pharmacology. Methods. We collected compounds and targets of RRER from traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) and SwissTargetPrediction. GC targets were obtained from GeneCards. Protein-protein interaction (PPI) network and RRER-GC-target network were built by STRING and Cytoscape 3.2.1. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed using Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results. We obtained 92 compounds of RRER. A total of 10 key compounds and 20 key targets were selected by RRER-GC-target network topological analysis. GO analysis showed that the biological process mainly involved in response to the tumor necrosis factor, positive regulation of fibroblast proliferation, and DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest. Molecular functions included cyclin-dependent protein serine/threonine kinase activity, RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding, and transmembrane receptor protein tyrosine kinase activity. Cellular components mainly were centrosome, cell surface, and membrane. KEGG pathway enrichment results mainly involved in the p53 signaling pathway, estrogen signaling pathway, and regulation of lipolysis in adipocytes. Conclusion. This study explored the anti-GC mechanism of RRER from the perspective of TME based on network pharmacology, which contributed to the development and application of RRER.
14 August 2026 in SSRN Electronic Journal
Herbal prescription recommendation (HPR) in traditional Chinese medicine (TCM) is a challenging clinical decision-support task that requires fusing heterogeneous patient information, domain knowledge, and institution-specific clinical constraints. Although recent methods leveraging deep learning and large language models (LLMs) have advanced this task, their limited use of these complementary sources may constrain prescription accuracy and weaken clinical safety assurance. To address these limitations, we propose ReaRx, a novel deep learning model for personalized and safe prescription recommendation. ReaRx comprises a prescription reasoning module and a prescription refinement module, which together emulate the clinical workflow of TCM physicians. The prescription reasoning module fuses heterogeneous clinical information to enhance patient representation and generate foundational prescriptions. For the prescription refinement module, we introduce an expert-guided herbal prescription refinement framework, named EGHPR, which incorporates institution-specific guidelines into a multi-step decision-making process within a policy-based reinforcement learning framework to iteratively refine the generated prescriptions. Experimental results under five-fold cross-validation on the TCM-GCD dataset demonstrate that ReaRx achieves state-of-the-art performance. Ablation studies, parameter analysis, and case studies further validate the effectiveness and practicality of the proposed modules. EGHPR can also be seamlessly integrated into existing LLM-based prescription recommendation models, improving prescription accuracy without retraining or updating the underlying models. Overall, ReaRx closely aligns with the clinical prescription process of TCM physicians, while EGHPR further enhances the accuracy, clinical relevance, and safety of generated prescriptions, demonstrating practical value for personalized and safe prescription recommendation.